Results 111 to 120 of about 64,353 (271)
The Role of RANBP3L in Pan‐Cancer With Its Significance in Hepatocellular Carcinoma
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background RAN binding protein 3‐like (RANBP3L), a member of the Ran‐binding protein family, has been linked to various cellular functions, but the role in cancer remains underexplored. In this research, we assessed the diagnostic and prognostic value of RANBP3L in pan‐cancer, especially in liver hepatocellular carcinoma (LIHC).
Beini Cen, Jie Li, Chao Wang
wiley +1 more source
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up [PDF]
, 2021 Parisa Malekzadeh +2 more
openalex +1 more source
Downregulation of TNFAIP3 Associated With Poor Prognosis and Immune Response in Breast Cancer
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background Breast cancer (BRCA) progression is closely linked to dysregulated inflammatory processes within the tumor microenvironment (TME). TNFAIP3, a key regulator of TNF‐α signaling, plays a dual role in cancer biology, but its precise function in BRCA pathogenesis and immune modulation remains unclear.
Yeqin Wu, Zhaoyang Qin, Gangping Wang
wiley +1 more source
PLEURAL MESOTHELIOMA: ETIOLOGY, INCIDENCE, DIAGNOSIS, TREATMENT AND SURVIVAL
, 2013 A. F Lazarev +4 more
openalex +2 more sources
Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.DCAF7 is up‐regulated in various tumours and correlates with poor prognosis, particularly in LIHC. High DCAF7 expression is linked to CD4+ T cell infiltration, up‐regulation of immune checkpoint genes and increased tumour mutational burden, suggesting a role in tumour immune escape.
Ruina Luan +6 more
wiley +1 more source
Malignant Pleura Mesothelioma: Clinical Perspectives [PDF]
, 2017 Konstantinos Grapatsas +16 more
openalex +1 more source
Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li +4 more
wiley +1 more source